Badiani B, Maratea D, Messori A. Second-line treatments for advanced gastric cancer: Interpreting outcomes by network meta-analysis. World J Clin Oncol 2015; 6(4): 73-79 [PMID: 26266104 DOI: 10.5306/wjco.v6.i4.73]
Corresponding Author of This Article
Dr. Andrea Messori, PhD, HTA Unit, ESTAV Toscana Centro, Regional Health Service, Via San Salvi 12, 50100 Firenze, Italy. andrea.messori.it@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Aug 10, 2015; 6(4): 73-79 Published online Aug 10, 2015. doi: 10.5306/wjco.v6.i4.73
Second-line treatments for advanced gastric cancer: Interpreting outcomes by network meta-analysis
Brigitta Badiani, Dario Maratea, Andrea Messori
Brigitta Badiani, Dario Maratea, Andrea Messori, HTA Unit, ESTAV Toscana Centro, Regional Health Service, 50100 Firenze, Italy
Author contributions: Badiani B performed the literature search and conducted the Bayesian meta-analysis; Maratea D checked the information from the clinical trials and contributed to the writing of the manuscript; Messori A wrote the manuscript and supervised all phases of the research.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at andrea.messori.it@gmail.com
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Andrea Messori, PhD, HTA Unit, ESTAV Toscana Centro, Regional Health Service, Via San Salvi 12, 50100 Firenze, Italy. andrea.messori.it@gmail.com
Fax: +39-5-74701319
Received: February 12, 2015 Peer-review started: February 14, 2015 First decision: March 6, 2015 Revised: April 8, 2015 Accepted: May 16, 2015 Article in press: May 18, 2015 Published online: August 10, 2015
Core Tip
Core tip: We carried out a Bayesian network meta-analysis to evaluate second-line treatments for advancer gastric cancer. After scanning the literature up to February 2015, 7 randomized controlled trials were included in our meta-analysis in which the treatments for this disease condition and best supportive care (BSC) were evaluated according to overall survival (OS). Our meta-analysis investigated 21 direct or indirect comparisons. The difference in OS between paclitaxel vs BSC and ramucirumab + paclitaxel vs BSC was statistically significant, while the other comparisons showed no statistical difference. In conclusion, our results indicate that both paclitaxel and ramucirumab + paclitaxel determine a significant prolongation in survival in comparison with BSC.
